Industry News: Pharma-biotech deals in neuroscience
Novartis – PTC Therapeutics - $2.9bn
December 2024 deal for a drug in phase 2 for Huntington’s, a neurological disease. Novartis paid $1bn upfront,
just to license the drug, not to acquire the biotech company. Additional future payments of a further $2bn.
Novartis will take over the development, manufacturing, and sales. PTC is also eligible to receive tiered double-digit royalties.
News link from Reuters
Abbvie - Aliada Therapeutics - $1.4bn
AbbVie acquired Aliada Therapeutics by for $1.4 billion. This substantial value paid for a Phase 1 Alzheimer's drug highlights
the attractiveness and potential high returns in the field of neuroscience.
News link from Endpoint News
Bristol Myers Squibb (BMS) - Karuna Therapeutics - $14bn
Bristol Myers Squibb acquired Karuna Therapeutics for $14 billion. The deal included the experimental schizophrenia drug
"KarXT," which is being reviewed by the FDA and could potentially become a blockbuster medicine. KarXT is a novel type of
medication for schizophrenia with promising results in mid- to late-stage trials.
News link from Biopharma Dive
Abbvie - Cerevel Therapeutics - $8.7bn
AbbVie acquired Cerevel Therapeutics for $8.7 billion. This deal gave AbbVie access to Cerevel's innovative drugs,
particularly one in advanced testing for schizophrenia. Both Cerevel and Karuna Therapeutics are developing drugs
that target muscarinic receptors, offering new approaches to treating neurological disorders.
News link from Abbvie
Novartis - DTx Pharma - $1bn
Novartis acquired DTx Pharma, a preclinical stage neuroscience biotech company specializing in RNA-based therapeutics.
News link from PMLiVE
Merck - Caraway Therapeutics - $610m
Merck entered into a collaboration with Caraway Therapeutics to develop drugs preclinical-stage drugs for the treatment of neurological disorders,
including Parkinson's disease. The collaboration aimed to leverage Caraway's expertise in protein degradation to target
disease-related proteins.
News link from Biospace
